Other languages Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Market Closed - Nasdaq Other stock markets 01:30:01 03/05/2024 am IST			5-day change	1st Jan Change
40.93 ^USD	+4.02%		+10.56%	+3.20%

17/04	Sector Update: Health Care Stocks Mixed Wednesday Afternoon	MT
17/04	Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	29/02
Sector Update: Health Care Stocks Weaker Monday Afternoon	27/02
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	26/02
Sector Update: Health Care Stocks Mixed Premarket Monday	26/02
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	26/02
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02
Celldex Therapeutics Prices $200.5 Million Share Offering	08/11
Celldex Shares Rise as Phase 2 Trial Shows Barzolvolimab Meets Primary Efficacy Endpoint for Chronic Spontaneous Urticaria	07/11
Sector Update: Health Care Stocks Advance Premarket Monday	06/11
Traders Await Next Catalyst as US Equity Futures Edge Higher Pre-Bell	06/11
Sector Update: Health Care	06/11
Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	06/11
Top Premarket Gainers	06/11
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	06/11
Celldex Therapeutics Says Prurigo Nodularis Phase 1b Study of Barzolvolimab Showed 'Durable Reductions in Itch'	06/11
Celldex Therapeutics Q3 Net Loss Widens, Revenue Rises	03/11
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023	26/23/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Other languages

Filters